SEMARION
Semarion is a spin-out company from the Cavendish Laboratory at the University of Cambridge, operating at the edge of the physical and life sciences. Semarion combines microchip industry materials and techniques engineering and cell biology to tackle unmet drug screening needs.
SEMARION
Industry:
Biotechnology Health Care Therapeutics
Founded:
2018-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.semarion.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
2.39 M GBP
Investors List
Parkwalk Advisors
Parkwalk Advisors investment in Seed Round - Semarion
Martlet Capital
Martlet Capital investment in Seed Round - Semarion
University of Cambridge Enterprise
University of Cambridge Enterprise investment in Seed Round - Semarion
Start Codon
Start Codon investment in Pre Seed Round - Semarion
Official Site Inspections
http://www.semarion.com Semrush global rank: 6.9 M Semrush visits lastest month: 708
- Host name: 18.133.230.35.bc.googleusercontent.com
- IP address: 35.230.133.18
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Semarion"
Semarion Ltd.'s All | Lab Manager
Semarion Ltd.'s All on Lab ManagerSemarion is built on fostering collaboration across disciplines to tackle foundational bottlenecks in drug discovery. We operate at the edge of the physical …See details»
Semarion - Crunchbase Company Profile & Funding
Semarion leverages microfabrication technology to build smart materials and develop novel cell assaying applications.See details»
Semarion - LinkedIn
Semarion is a spin-out from Cambridge University with a mission to accelerate the pace of drug discovery. We are revolutionising adherent cell screening to produce better data, faster. Our …See details»
Semarion - Company Profile - pharmaservicesdirectory.com
Company Activities Semarion is a spin-out from Cambridge University with a mission to accelerate the pace of drug discovery. We are revolutionising adherent cell screening to produce better …See details»
Semarion - VentureRadar
Semarion is a company that accelerates drug discovery with its SemaCyte® microcarrier platform. Their technology uses novel materials to move and freeze adherent cells, enhancing cell …See details»
Semarion Company Profile - Office Locations, Competitors ... - Craft
Semarion has 5 employees at their 1 location and $3.53 m in total funding,. See insights on Semarion including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
Semarion | About
Semarion is built on fostering collaboration across disciplines to tackle foundational bottlenecks in drug discovery. We operate at the edge of the physical and life sciences by using microchip industry materials and …See details»
Semarion - 2022 - Wiley Analytical Science
Mar 7, 2022 Innovating Across Disciplines: Semarion is built on fostering collaboration across disciplines to tackle foundational bottlenecks in drug discovery. The company operates at the …See details»
Semarion 2025 Company Profile: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Semarion. Use the PitchBook Platform to explore the full profile.See details»
Semarion secures £2.0m in latest funding round
Mar 17, 2025 Semarion’s proprietary technology directly addresses these bottlenecks. Since its inception, Semarion has raised £2.4M in equity funding to develop and validate its core …See details»
Semarion | Semarion raises £2.14m seed funding to commercialise …
Feb 22, 2022 Semarion business news: £2.14 million GBP seed round with Parkwalk Advisors, Cambridge Enterprise, and Martlet Capital.See details»
Semarion - YouTube
Semarion is a spin-out company from the Cavendish Laboratory at the University of Cambridge, operating at the edge of the physical and life sciences. By using microchip industry materials …See details»
Semarion | VentureRadar
Semarion is an early-stage drug screening and lead identification company focussed on the discovery of first-in-class, GPCR-targeting oncology drugs. Our SemaCyte Platform, …See details»
Semarion Careers, Perks + Culture | Built In
Semarion is a spin-out from Cambridge University with a mission to accelerate the pace of drug discovery. We are revolutionising adherent cell screening to produce better data, faster. Our …See details»
Careers - Semarion
Learn more about careers at Semarion. We offer exciting opportunities in a dynamic interdisciplinary technology company.See details»
News - Semarion
Feb 22, 2022 Find out more about Semarion by reading recent news articles, including those on events, partnering, business, and technology.See details»
Semarion at SLAS 2025 | Accelerating Drug Discovery with …
Mar 31, 2025 In this short interview from SLAS 2025 in San Diego, Semarion CEO Jeroen Verheyen shares how Semarion is solving key bottlenecks in in vitro drug discovery.S...See details»
Geron Appoints Harout Semerjian as President and Chief Executive …
4 days ago Industry veteran brings 30+ years of commercial hematology and oncology experience to help accelerate Geron’s next phase of growth Geron Corporation (Nasdaq: …See details»
Semarion | Order & Support
Throughout the process, the Semarion team provides hands-on support to ensure smooth adoption, allowing you to unlock the full potential of the SemaCyte® Microcarriers. Order …See details»
Semarion | Semarion Introduces SemaCyte Multiplexing Platform …
Mar 20, 2024 Semarion Introduces SemaCyte Multiplexing Platform to Enhance Cell Assay Data Quality and Speed During Drug Discovery Expansion to SemaCyte Microcarrier platform …See details»